1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. The Lancet 1896;148:162-5.

2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.

3. National Comprehensive Cancer Network. About the NCCN clinical practice guidelines in oncology (NCCN guidelines®). Available from: [Last accessed on 5 Nov 2018].

4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.

5. Trop I, LeBlanc SM, David J, Lalonde L, Tran-Thanh D, et al. Molecular classification of infiltrating breast cancer: toward personalized therapy. Radiographics 2014;34:1178-95.

6. Morigi C. Highlights from the 15th St Gallen International Breast Cancer Conference 15-18 March,. 2017, Vienna: tailored treatments for patients with early breast cancer. Ecancermedicalscience 2017;11:732.

7. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010;363:1938-48.

8. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007;9:R65.

9. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.

10. Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014;6:2187-223.

11. Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res 2016;6:1609-23.

12. Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, et al. Triple-negative breast cancer: new perspectives for targeted therapies. OncoTargets Ther 2015;8:177-93.

13. Bousquet G, Feugeas JP, Ferreira I, Vercellino L, Jourdan N, et al. Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma. Breast Cancer Res 2014;16:401.

14. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 2012;14:R11.

15. Pompili L, Porru M, Caruso C, Biroccio A, Leonetti C. Patient-derived xenografts: a relevant preclinical model for drug development. J Exp Clin Cancer Res 2016;35:189.

16. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011;10:3-8.

17. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011;10:1311-6.

18. Tabernero J, Kunzmann V, Scheithauer W, Reni M, Shiansong Li J, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial. OncoTargets Ther 2017;10:591-6.

19. Bousquet G, Janin A. Patient-derived xenograft: an adjuvant technology for the treatment of metastatic disease. Pathobiology 2016;83:170-6.

20. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7.

21. O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 2016;280:576-84.

22. Baselga J, Gómez P, Greil R, Braga S, Climent MA, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013;31:2586-92.

23. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010;11:753-62.

24. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.

25. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.

26. Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013;19:5505-12.

27. Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, et al. A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol 2016;27:812-8.

28. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-71.

29. Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, et al. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 2013;15:R37.

30. Gonçalves A, Bertucci F, Guille A, Garnier S, Adelaide J, et al. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. Oncotarget 2016;7:79428-41.

31. Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat Commun 2015;6:8305.

32. Krepler C, Xiao M, Sproesser K, Brafford PA, Shannan B, et al. Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies. Clin Cancer Res 2016;22:1592-602.

Journal of Translational Genetics and Genomics
ISSN 2578-5281 (Online)
Follow Us


All published articles are preserved here permanently:


All published articles are preserved here permanently: